CTP-dependent molecular switches: an emerging new principle in cellular regulation

C SWITCH aims to explore the diverse roles of CTP-dependent C-switch proteins in cellular regulation and their potential as novel antibacterial targets to combat antibiotic resistance.

Subsidie
€ 2.082.419
2023

Projectdetails

Introduction

Nucleotide-dependent molecular switches play key roles in the regulation of cellular processes such as translation, protein folding and transport, cytoskeletal dynamics, and cell differentiation. Until recently, their function was thought to rely exclusively on the purine nucleotides GTP or ATP as cofactors. This paradigm changed in 2019, when my group identified a fundamentally new class of regulatory switches, now called C-switches, that depend on the pyrimidine nucleotide CTP.

Importance of C-switches

The few C-switches studied to date have important functions in bacterial growth and pathogenicity. Database searches predict that C-switches are highly diverse and widespread in nature. However, the physiological roles and modes of action of these proteins are still largely enigmatic.

Objectives of C SWITCH

The overarching goal of C SWITCH is to provide comprehensive insight into the biology of C-switches and clarify the ways in which this newly identified regulatory principle can control protein activity and cellular functions.

Methodology

For this purpose, we will employ both bioinformatic and experimental methods to:

  1. Systematically identify new types of C-switch proteins.
  2. Perform detailed mechanistic studies of prototypic representatives, using state-of-the-art in vitro and in vivo approaches.

Impact of C-SWITCH

C-SWITCH will thus break new ground in the understanding of cellular regulation and pave the way to a global understanding of C-switches as versatile regulators in biology.

Pharmacological Potential

Importantly, proteins containing a canonical C-switch domain are absent from humans and other mammalian systems. C-SWITCH will therefore also explore the pharmacological potential of C-switches as new targets for antibacterial and antivirulence therapies, thereby possibly opening new avenues for translational applications and supporting the current global effort to combat bacterial antibiotic resistance.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.082.419
Totale projectbegroting€ 2.082.419

Tijdlijn

Startdatum1-10-2023
Einddatum30-9-2028
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • PHILIPPS UNIVERSITAET MARBURGpenvoerder

Land(en)

Germany

Vergelijkbare projecten binnen European Research Council

ERC Starting...

Designing Allosteric Protein Switches by In Vivo Directed Evolution and Computational Inference

DaVinci-Switches aims to revolutionize switchable protein engineering by combining synthetic biology and machine learning to create light- and drug-inducible proteins for regenerative medicine applications.

€ 1.619.687
ERC Starting...

Cracking the Post-Translational Modification Crosstalk Code in S. cerevisiae

This project aims to systematically investigate post-translational modification crosstalk in S. cerevisiae using CRISPR-based methods to uncover regulatory mechanisms across biological processes.

€ 1.489.798
ERC Starting...

Chemical biology of intracellular cholesterol transport

ChemBioChol aims to develop selective small molecule modulators for cholesterol transport proteins to elucidate their roles in lipid metabolism and potential therapeutic applications in diseases.

€ 1.499.786
ERC Starting...

NTase Products and Cyclic Nucleotide Signalling

This project aims to discover novel cyclic nucleotides and their signaling pathways in humans, focusing on uncharacterized nucleotidyltransferases to enhance immune responses and therapeutic options.

€ 1.755.873
ERC Starting...

FROM SINGLE MOLECULES TO CELL REPROGRAMMING: DECIPHERING AND RECODING DISORDERED PIONEER TRANSCRIPTION FACTORS

This project aims to elucidate the molecular mechanisms of pioneer transcription factors using single-molecule spectroscopy to enhance control over cell fate for therapeutic applications.

€ 1.500.000